Advisor and Founder

Chief Commercial Officer

Regulatory actions for June 6, 2025

EC approves Santen’s Ryjunea to slow progression of pediatric myopia

EC approves Santen’s Ryjunea to slow progression of paediatric myopia

Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia

Director Commercial Operations

Sydnexis Inc. is a clinical-stage biopharmaceutical company focused on helping children see clearly through innovative eye care solutions. The Director of Commercial Operations will lead initiatives to enhance commercial productivity and performance, collaborating with senior leadership and various teams to drive revenue growth and operational excellence.

Sign up with Google

Sign in with Google